Unknown

Dataset Information

0

In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor.


ABSTRACT: The insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane receptor with tyrosine kinase activity. The receptor plays a critical role in cancer. Using monoclonal antibodies (MAbs) against the IGF-1R, typically blocks ligand binding and enhances down-regulation of the cell-surface IGF-1R. Some MAbs such as cixutumumab are under clinical trial investigation. Targeting multiple distinct epitopes on IGF-1R, might be an effective strategy to inhibit IGF-1R pathway in cancer. In this study, new linear B cell epitopes for the extracellular domains of IGF-1R were predicted by in silico methods using a combination of linear B cell epitope prediction web servers such as ABCpred, Bepired, BCPREDs, Bcepred and Elliprro. Moreover, Discotope, B- pred and PEPOP web server tools were employed to predict new conformational B cell epitopes. In contrast to previously reported epitopes from extracellular region of the IGF-1R, we predicted new linear P8: (RQPQDGYLYRHNYCSK) and conformational Pc4: (HYYYAGVCVPACPPNTYRFE), Ppc6: (KMCPSTGKRENNESAPDNDT) and Ppc20: (ANILSAESSDSEFMQEPSGFI) epitopes. These epitopes are useful for further study as peptide antigens to actively immune host animals to develop new MAbs. Furthermore, the epitopes can be used in peptide-based cancer vaccines design.

SUBMITTER: Bayrami V 

PROVIDER: S-EPMC5326484 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor.

Bayrami Vahid V   Keyhanfar Mehrnaz M   Mohabatkar Hassan H   Mahdavi Manijeh M   Moreau Violaine V  

Molecular biology research communications 20161201 4


The insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane receptor with tyrosine kinase activity. The receptor plays a critical role in cancer. Using monoclonal antibodies (MAbs) against the IGF-1R, typically blocks ligand binding and enhances down-regulation of the cell-surface IGF-1R. Some MAbs such as cixutumumab are under clinical trial investigation. Targeting multiple distinct epitopes on IGF-1R, might be an effective strategy to inhibit IGF-1R pathway in cancer. In this study,  ...[more]

Similar Datasets

| S-EPMC9626938 | biostudies-literature
| S-EPMC4501001 | biostudies-literature
| S-EPMC8109234 | biostudies-literature
| S-EPMC3039292 | biostudies-literature
| S-EPMC9364964 | biostudies-literature
| S-EPMC4224629 | biostudies-literature
| S-EPMC6040160 | biostudies-literature
| S-EPMC3062653 | biostudies-literature
| S-EPMC9316817 | biostudies-literature
| S-EPMC1702556 | biostudies-literature